Accera Blames Alzheimer’s Clinical Trial Failure on Low Uptake of Oral Drug AC-1204

Accera Blames Alzheimer’s Clinical Trial Failure on Low Uptake of Oral Drug AC-1204
Yet another Alzheimer’s disease clinical trial (NCT01741194) has ended in disappointment. Accera, noting that its Phase 3 trial of AC-1204 showed the drug offered no benefits over placebo, blamed its failure on an inadequate uptake of AC-1204 into the bloodstream. “The trial result is disappointing for us and the millions of patients, caregivers and physicians who urgently need

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. James Tripp says:

    Stop wasting time, money, and resources chasing treatment via ‘synthesized’ chemical compounds and invest in the existing natural treatment and cure available in phytocannabinoids.

    ———————

    June 27, 2016
    Cannabinoids remove plaque-forming Alzheimer’s proteins from brain cells

    Preliminary lab studies at the Salk Institute find THC reduces beta amyloid proteins in human neurons
    ———————–
    http://www.salk.edu/news-release/cannabinoids-remove-plaque-forming-alzheimers-proteins-from-brain-cells/

Leave a Comment

Your email address will not be published. Required fields are marked *